138 related articles for article (PubMed ID: 38643944)
1. Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant.
Khoury R; Grimley MS; Nelson AS; Leemhuis T; Cancelas JA; Cook E; Wang Y; Heyenbruch D; Bollard CM; Keller MD; Hanley PJ; Lutzko C; Pham G; Davies SM; Rubinstein JD
Am J Transplant; 2024 Apr; ():. PubMed ID: 38643944
[TBL] [Abstract][Full Text] [Related]
2. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
[TBL] [Abstract][Full Text] [Related]
3. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
[TBL] [Abstract][Full Text] [Related]
4. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant.
Jiang W; Clancy LE; Avdic S; Sutrave G; Street J; Simms R; McGuire HM; Patrick E; Chan AS; McCaughan G; Myers N; Micklethwaite KP; Antonenas V; Selim AG; Ritchie D; Bateman CM; Shaw PJ; Blyth E; Gottlieb DJ
Blood Adv; 2022 Sep; 6(17):4949-4966. PubMed ID: 35819448
[TBL] [Abstract][Full Text] [Related]
5. Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.
Nelson AS; Heyenbruch D; Rubinstein JD; Sabulski A; Jodele S; Thomas S; Lutzko C; Zhu X; Leemhuis T; Cancelas JA; Keller M; Bollard CM; Hanley PJ; Davies SM; Grimley MS
Blood Adv; 2020 Nov; 4(22):5745-5754. PubMed ID: 33216887
[TBL] [Abstract][Full Text] [Related]
6. Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.
Anderson-Smits C; Baker ER; Hirji I
Transpl Infect Dis; 2020 Dec; 22(6):e13396. PubMed ID: 32603496
[TBL] [Abstract][Full Text] [Related]
7. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein JD; Lutzko C; Leemhuis T; Zhu X; Pham G; Ray L; Thomas S; Dourson C; Wilhelm J; Lane A; Cancelas JA; Lipps D; Ferrell J; Hanley PJ; Keller MD; Bollard CM; Wang YM; Davies SM; Nelson AS; Grimley MS
Blood Adv; 2022 May; 6(9):2897-2907. PubMed ID: 35108727
[TBL] [Abstract][Full Text] [Related]
8. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
9. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
Mahadeo KM; Baiocchi R; Beitinjaneh A; Chaganti S; Choquet S; Dierickx D; Dinavahi R; Duan X; Gamelin L; Ghobadi A; Guzman-Becerra N; Joshi M; Mehta A; Navarro WH; Nikiforow S; O'Reilly RJ; Reshef R; Ruiz F; Spindler T; Prockop S
Lancet Oncol; 2024 Mar; 25(3):376-387. PubMed ID: 38309282
[TBL] [Abstract][Full Text] [Related]
10. The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.
AlDabbagh MA; Gitman MR; Kumar D; Humar A; Rotstein C; Husain S
Am J Transplant; 2017 Mar; 17(3):770-781. PubMed ID: 27545492
[TBL] [Abstract][Full Text] [Related]
11. A cost-effective strategy for selection of third-party donors for a virus-specific T-cell bank for an Asian patient population.
Linn YC; Sundar Raj K; Teo B; Phang CY; Chittezhath M; Koh M
Cytotherapy; 2023 May; 25(5):510-520. PubMed ID: 36882347
[TBL] [Abstract][Full Text] [Related]
12. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
13. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.
Qian C; Campidelli A; Wang Y; Cai H; Venard V; Jeulin H; Dalle JH; Pochon C; D'aveni M; Bruno B; Paillard C; Vigouroux S; Jubert C; Ceballos P; Marie-Cardine A; Galambrun C; Cholle C; Clerc Urmes I; Petitpain N; De Carvalho Bittencourt M; Decot V; Reppel L; Salmon A; Clement L; Bensoussan D
J Hematol Oncol; 2017 May; 10(1):102. PubMed ID: 28482908
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
[TBL] [Abstract][Full Text] [Related]
16. Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.
Withers B; Blyth E; Clancy LE; Yong A; Fraser C; Burgess J; Simms R; Brown R; Kliman D; Dubosq MC; Bishop D; Sutrave G; Ma CKK; Shaw PJ; Micklethwaite KP; Gottlieb DJ
Blood Adv; 2017 Nov; 1(24):2193-2205. PubMed ID: 29296867
[TBL] [Abstract][Full Text] [Related]
17. Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry.
Eiz-Vesper B; Maecker-Kolhoff B; Blasczyk R
Front Immunol; 2012; 3():410. PubMed ID: 23372567
[TBL] [Abstract][Full Text] [Related]
18. EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review.
Liu JY; Zhang JM; Zhan HS; Sun LY; Wei L
Transpl Int; 2021 Dec; 34(12):2483-2493. PubMed ID: 34510581
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus DNAemia in Iranian liver transplant recipients and assessment of its variation in posttransplant lymphproliferative disorder patients by quantitative polymerase chain reaction assay.
Jamalidoust M; Geramizadeh B; Pouladfar G; Namayandeh M; Asaie S; Aliabadi N; Nikeghbalian S; Ziyaeyan M
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():306-11. PubMed ID: 25894179
[TBL] [Abstract][Full Text] [Related]
20. Role of Cytomegalovirus in the Development of Posttransplant Lymphoproliferative Disorders With or Without Epstein-Barr Virus Infection.
Namayandeh M; Jamalidoust M; Pouladfar G; Zare M; Ziyaeyan M
Exp Clin Transplant; 2022 Aug; 20(8):757-761. PubMed ID: 35037609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]